Suppr超能文献

从人婴儿粪便样本中分离的益生菌乳杆菌对巨噬细胞内 1 型的修复作用。

Remediation of intramacrophageal type 1 by probiotic lactobacilli isolated from human infants' stool samples.

机构信息

Department of Microbial Biotechnology, Panjab University, Chandigarh, India.

Department of Microbiology, Panjab University, Chandigarh, India.

出版信息

Indian J Med Res. 2017 May;145(5):679-686. doi: 10.4103/ijmr.IJMR_1212_14.

Abstract

BACKGROUND & OBJECTIVES: Shigella dysenteriae is one of the most virulent pathogens causing bacillary dysentery and is responsible for high mortality in infants. To reduce the load of antibiotic therapy for treating shigellosis, this study was carried out to assess the ex vivo effect of novel probiotic lactobacilli, isolated from infant's stool samples, on killing S. dysenteriae type 1 residing in the rat macrophages.

METHODS

Stool samples from infants were collected, processed for the isolation of lactobacilli and screened for the probiotic attributes (acid tolerance, bile tolerance, ability to adhere intestinal cells and anti-S. dysenteriae activity). The effect of cell-free supernatant of lactobacilli on Shigella- infected macrophages in terms of phagocytic ability, extent of lipid peroxidation, nitrite, superoxide dismutase and glutathione levels was evaluated.

RESULTS

Based on the probiotic attributes, three lactobacilli were isolated from the stool samples of infants. Using classical and molecular tools, these isolates were identified as Lactobacillus pentosus, L. Paraplantarum and L. rhamnosus. All the three lactobacilli had the ability to kill intramacrophage S. dysentriae type 1. The anti-Shigella activity of the probiotic lactobacilli was attributed to increased antioxidative ability and decreased free radical production by the infected macrophages.

INTERPRETATION & CONCLUSIONS: Probiotic cocktail of L. pentosus, L. paraplantarum and L. rhamnosus showed ex vivo killing of S. dysenteriae residing inside the rat macrophages significantly. This cocktail has the potential to be used as a natural alternative for treating S. dysenteriae infection, especially in infants, however, further studies need to be done to confirm these finding in vivo.

摘要

背景与目的

志贺氏菌是导致细菌性痢疾的最具毒性的病原体之一,也是导致婴儿死亡率高的原因。为了减少治疗志贺氏菌病的抗生素治疗负担,本研究评估了从婴儿粪便样本中分离出来的新型益生菌乳杆菌在体外对驻留在大鼠巨噬细胞中的志贺氏菌 1 型的杀伤作用。

方法

收集婴儿的粪便样本,用于分离乳杆菌并筛选益生菌属性(耐酸、耐胆汁、黏附肠细胞的能力和抗志贺氏菌活性)。评估乳杆菌细胞外上清液对志贺氏菌感染的巨噬细胞的吞噬能力、脂质过氧化程度、亚硝酸盐、超氧化物歧化酶和谷胱甘肽水平的影响。

结果

基于益生菌属性,从婴儿粪便样本中分离出三种乳杆菌。使用经典和分子工具,这些分离株被鉴定为戊糖乳杆菌、副干酪乳杆菌和鼠李糖乳杆菌。所有三种乳杆菌都有能力杀死巨噬细胞内的志贺氏菌 1 型。益生菌乳杆菌的抗志贺氏菌活性归因于感染巨噬细胞抗氧化能力的提高和自由基生成的减少。

解释与结论

戊糖乳杆菌、副干酪乳杆菌和鼠李糖乳杆菌的益生菌混合物在体外显著杀死了驻留在大鼠巨噬细胞内的志贺氏菌。这种混合物有可能被用作治疗志贺氏菌感染的天然替代品,特别是在婴儿中,然而,需要进一步的研究来在体内证实这些发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21c0/5644304/fd665247e0c1/IJMR-145-679-g005.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验